Malignant Mesothelioma - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 372 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Malignant Mesothelioma - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Malignant Mesothelioma - Pipeline Review, H2 2015', provides an overview of the Malignant Mesothelioma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Malignant Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Mesothelioma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Malignant Mesothelioma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Malignant Mesothelioma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Malignant Mesothelioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Malignant Mesothelioma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Malignant Mesothelioma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Malignant Mesothelioma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Malignant Mesothelioma Overview 10
Therapeutics Development 11
Pipeline Products for Malignant Mesothelioma - Overview 11
Pipeline Products for Malignant Mesothelioma - Comparative Analysis 12
Malignant Mesothelioma - Therapeutics under Development by Companies 13
Malignant Mesothelioma - Therapeutics under Investigation by Universities/Institutes 18
Malignant Mesothelioma - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Malignant Mesothelioma - Products under Development by Companies 22
Malignant Mesothelioma - Products under Investigation by Universities/Institutes 26
Malignant Mesothelioma - Companies Involved in Therapeutics Development 27
Aduro BioTech, Inc. 27
Advantagene, Inc. 28
Aeolus Pharmaceuticals, Inc. 29
Amphera BV 30
AnGes MG, Inc. 31
arGEN-X BV 32
ArQule, Inc. 33
AVEO Pharmaceuticals, Inc. 34
Bayer AG 35
Berg LLC 36
Biogen, Inc. 37
Bionomics Limited 38
Biotecnol, Inc. 39
Boehringer Ingelheim GmbH 40
Boston Biomedical, Inc. 41
Bristol-Myers Squibb Company 42
Calithera Biosciences, Inc. 43
CanBas Co., Ltd. 44
Concordia Healthcare Corp. 45
CritiTech, Inc. 46
Deciphera Pharmaceuticals, LLC 47
Eagle Pharmaceuticals, Inc. 48
Eisai Co., Ltd. 49
Eli Lilly and Company 50
EnGeneIC Ltd 51
F. Hoffmann-La Roche Ltd. 52
Five Prime Therapeutics, Inc. 53
Genelux Corporation 54
GlaxoSmithKline Plc 55
Juno Therapeutics Inc. 56
Karyopharm Therapeutics, Inc. 57
Kyowa Hakko Kirin Co., Ltd. 58
MedImmune, LLC 59
Merck & Co., Inc. 60
Merck KGaA 61
Millennium Pharmaceuticals, Inc. 62
MolMed S.p.A. 63
Morphotek, Inc. 64
Novartis AG 65
Ono Pharmaceutical Co., Ltd. 66
Oxford BioMedica Plc 67
Pfizer Inc. 68
Pharma Mar, S.A. 69
Polaris Pharmaceuticals, Inc. 70
Progenra, Inc. 71
Sellas Inc. 72
Sorrento Therapeutics, Inc. 73
Synta Pharmaceuticals Corp. 74
Targovax AS 75
TRACON Pharmaceuticals, Inc. 76
VasGene Therapeutics, Inc. 77
Verastem, Inc. 78
Virttu Biologics Limited 79
Y's Therapeutics Co., Ltd. 80
Malignant Mesothelioma - Therapeutics Assessment 81
Assessment by Monotherapy Products 81
Assessment by Combination Products 82
Assessment by Target 83
Assessment by Mechanism of Action 86
Assessment by Route of Administration 89
Assessment by Molecule Type 91
Drug Profiles 93
Ad5-SGE-REIC/Dkk3 - Drug Profile 93
AEOL-10150 - Drug Profile 95
alisertib - Drug Profile 98
amatuximab - Drug Profile 102
anetumab ravtansine - Drug Profile 105
ARGX-110 - Drug Profile 107
ascrinvacumab - Drug Profile 110
AV-203 - Drug Profile 111
avelumab - Drug Profile 112
bevacizumab - Drug Profile 114
BG-00001 - Drug Profile 120
BIW-8962 - Drug Profile 121
BMS-986148 - Drug Profile 122
BNC-105 - Drug Profile 123
CB-839 - Drug Profile 125
CBP-501 - Drug Profile 127
Cellular Immunotherapy 2 for Oncology - Drug Profile 129
Cellular Immunotherapy for Cancer - Drug Profile 130
Cellular Immunotherapy for Malignant Pleural Mesothelioma and Advanced Leukemia - Drug Profile 131
Cellular Immunotherapy to Target CSPG4 for Oncology - Drug Profile 132
CRS-207 - Drug Profile 133
Dendritic Cell Therapy for Oncology and Infectious Disease - Drug Profile 136
DP-3975 - Drug Profile 137
DPV-001 - Drug Profile 138
E-7449 - Drug Profile 140
FL-118 - Drug Profile 141
FP-1039 - Drug Profile 144
ganetespib - Drug Profile 146
GEN-0101 - Drug Profile 151
Gene Therapy for Malignant Pleural Mesothelioma - Drug Profile 153
Gene Therapy to Activate NK4 for Malignant Pleural Mesothelioma - Drug Profile 154
GLONC-1 - Drug Profile 155
GSK-2256098 - Drug Profile 158
HSV-1716 - Drug Profile 160
iCasp9M28z - Drug Profile 163
JTCR-016 - Drug Profile 164
KPT-251 - Drug Profile 165
LY-3023414 - Drug Profile 166
MesoCancerVac - Drug Profile 168
MesoCART - Drug Profile 169
Monoclonal Antibody Conjugated to Target Mesothelin for Oncology - Drug Profile 170
MV-NIS - Drug Profile 172
napabucasin - Drug Profile 174
NGR-hTNF - Drug Profile 177
nintedanib - Drug Profile 181
nivolumab - Drug Profile 186
ONCOS-102 - Drug Profile 194
Oshadi D + Oshadi R - Drug Profile 196
OXB-301 - Drug Profile 197
P-0005091 - Drug Profile 200
paclitaxel - Drug Profile 201
pegargiminase - Drug Profile 202
pembrolizumab - Drug Profile 206
pemetrexed disodium - Drug Profile 215
porfimer sodium - Drug Profile 216
rAd-IFN - Drug Profile 218
Small Molecules to Inhibit Bcl-2 Survival Proteins for Cancer - Drug Profile 220
Stem Cell Therapy to Target TRAIL Receptor for Malignant Pleural Mesothelioma and Mestatic Lung Cancer - Drug Profile 221
TargomiRs - Drug Profile 222
Tb-535 - Drug Profile 224
tivantinib - Drug Profile 225
trabectedin - Drug Profile 227
TRC-102 - Drug Profile 232
tremelimumab - Drug Profile 234
ubidecarenone - Drug Profile 237
Vaccine for Cancer - Drug Profile 239
Vaccine to Target WT1 for Cancer - Drug Profile 240
Vas-01 - Drug Profile 241
VS-4718 - Drug Profile 243
VS-5584 - Drug Profile 244
YS-110 - Drug Profile 246
Malignant Mesothelioma - Recent Pipeline Updates 247
Malignant Mesothelioma - Dormant Projects 354
Malignant Mesothelioma - Discontinued Products 356
Malignant Mesothelioma - Product Development Milestones 357
Featured News & Press Releases 357
Appendix 366
Methodology 366
Coverage 366
Secondary Research 366
Primary Research 366
Expert Panel Validation 366
Contact Us 366
Disclaimer 367

List of Tables

Number of Products under Development for Malignant Mesothelioma, H2 2015 16
Number of Products under Development for Malignant Mesothelioma - Comparative Analysis, H2 2015 17
Number of Products under Development by Companies, H2 2015 19
Number of Products under Development by Companies, H2 2015 (Contd..1) 20
Number of Products under Development by Companies, H2 2015 (Contd..2) 21
Number of Products under Development by Companies, H2 2015 (Contd..3) 22
Number of Products under Investigation by Universities/Institutes, H2 2015 23
Comparative Analysis by Late Stage Development, H2 2015 24
Comparative Analysis by Clinical Stage Development, H2 2015 25
Comparative Analysis by Early Stage Development, H2 2015 26
Products under Development by Companies, H2 2015 27
Products under Development by Companies, H2 2015 (Contd..1) 28
Products under Development by Companies, H2 2015 (Contd..2) 29
Products under Development by Companies, H2 2015 (Contd..3) 30
Products under Investigation by Universities/Institutes, H2 2015 31
Malignant Mesothelioma - Pipeline by Aduro BioTech, Inc., H2 2015 32
Malignant Mesothelioma - Pipeline by Advantagene, Inc., H2 2015 33
Malignant Mesothelioma - Pipeline by Aeolus Pharmaceuticals, Inc., H2 2015 34
Malignant Mesothelioma - Pipeline by Amphera BV, H2 2015 35
Malignant Mesothelioma - Pipeline by AnGes MG, Inc., H2 2015 36
Malignant Mesothelioma - Pipeline by arGEN-X BV, H2 2015 37
Malignant Mesothelioma - Pipeline by ArQule, Inc., H2 2015 38
Malignant Mesothelioma - Pipeline by AVEO Pharmaceuticals, Inc., H2 2015 39
Malignant Mesothelioma - Pipeline by Bayer AG, H2 2015 40
Malignant Mesothelioma - Pipeline by Berg LLC , H2 2015 41
Malignant Mesothelioma - Pipeline by Biogen, Inc., H2 2015 42
Malignant Mesothelioma - Pipeline by Bionomics Limited, H2 2015 43
Malignant Mesothelioma - Pipeline by Biotecnol, Inc., H2 2015 44
Malignant Mesothelioma - Pipeline by Boehringer Ingelheim GmbH, H2 2015 45
Malignant Mesothelioma - Pipeline by Boston Biomedical, Inc., H2 2015 46
Malignant Mesothelioma - Pipeline by Bristol-Myers Squibb Company, H2 2015 47
Malignant Mesothelioma - Pipeline by Calithera Biosciences, Inc., H2 2015 48
Malignant Mesothelioma - Pipeline by CanBas Co., Ltd., H2 2015 49
Malignant Mesothelioma - Pipeline by Concordia Healthcare Corp., H2 2015 50
Malignant Mesothelioma - Pipeline by CritiTech, Inc., H2 2015 51
Malignant Mesothelioma - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2015 52
Malignant Mesothelioma - Pipeline by Eagle Pharmaceuticals, Inc., H2 2015 53
Malignant Mesothelioma - Pipeline by Eisai Co., Ltd., H2 2015 54
Malignant Mesothelioma - Pipeline by Eli Lilly and Company, H2 2015 55
Malignant Mesothelioma - Pipeline by EnGeneIC Ltd, H2 2015 56
Malignant Mesothelioma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 57
Malignant Mesothelioma - Pipeline by Five Prime Therapeutics, Inc., H2 2015 58
Malignant Mesothelioma - Pipeline by Genelux Corporation, H2 2015 59
Malignant Mesothelioma - Pipeline by GlaxoSmithKline Plc, H2 2015 60
Malignant Mesothelioma - Pipeline by Juno Therapeutics Inc., H2 2015 61
Malignant Mesothelioma - Pipeline by Karyopharm Therapeutics, Inc., H2 2015 62
Malignant Mesothelioma - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2015 63
Malignant Mesothelioma - Pipeline by MedImmune, LLC, H2 2015 64
Malignant Mesothelioma - Pipeline by Merck & Co., Inc., H2 2015 65
Malignant Mesothelioma - Pipeline by Merck KGaA, H2 2015 66
Malignant Mesothelioma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015 67
Malignant Mesothelioma - Pipeline by MolMed S.p.A., H2 2015 68
Malignant Mesothelioma - Pipeline by Morphotek, Inc., H2 2015 69
Malignant Mesothelioma - Pipeline by Novartis AG, H2 2015 70
Malignant Mesothelioma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015 71
Malignant Mesothelioma - Pipeline by Oxford BioMedica Plc, H2 2015 72
Malignant Mesothelioma - Pipeline by Pfizer Inc., H2 2015 73
Malignant Mesothelioma - Pipeline by Pharma Mar, S.A., H2 2015 74
Malignant Mesothelioma - Pipeline by Polaris Pharmaceuticals, Inc., H2 2015 75
Malignant Mesothelioma - Pipeline by Progenra, Inc., H2 2015 76
Malignant Mesothelioma - Pipeline by Sellas Inc., H2 2015 77
Malignant Mesothelioma - Pipeline by Sorrento Therapeutics, Inc., H2 2015 78
Malignant Mesothelioma - Pipeline by Synta Pharmaceuticals Corp., H2 2015 79
Malignant Mesothelioma - Pipeline by Targovax AS, H2 2015 80
Malignant Mesothelioma - Pipeline by TRACON Pharmaceuticals, Inc., H2 2015 81
Malignant Mesothelioma - Pipeline by VasGene Therapeutics, Inc., H2 2015 82
Malignant Mesothelioma - Pipeline by Verastem, Inc., H2 2015 83
Malignant Mesothelioma - Pipeline by Virttu Biologics Limited, H2 2015 84
Malignant Mesothelioma - Pipeline by Y's Therapeutics Co., Ltd., H2 2015 85
Assessment by Monotherapy Products, H2 2015 86
Assessment by Combination Products, H2 2015 87
Number of Products by Stage and Target, H2 2015 89
Number of Products by Stage and Mechanism of Action, H2 2015 92
Number of Products by Stage and Route of Administration, H2 2015 95
Number of Products by Stage and Molecule Type, H2 2015 97
Malignant Mesothelioma Therapeutics - Recent Pipeline Updates, H2 2015 252
Malignant Mesothelioma - Dormant Projects, H2 2015 359
Malignant Mesothelioma - Dormant Projects (Contd..1), H2 2015 360
Malignant Mesothelioma - Discontinued Products, H2 2015 361